Does ethnicity affect blood pressure regulation?

Cardiovascular and metabolic responses to glucose in South Asians and Caucasians: the impact of ethnicity on blood pressure regulation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN38424862

Enrollment

Registered

2018-12-04

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood pressure regulation Circulatory System Blood pressure regulation

Interventions

Participants enter the study in a randomised fashion after an initial recruitment process. The order of the subject’s test entry before the very first test will be randomised by using a random sequenc

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Healthy 2. Non-smoking 3. EITHER of South Asian ancestry (India, Pakistan, Bangladesh, Sri Lanka or Nepal) OR Caucasian 4. BMI between 18.5 and 24.9 kg/m² 5. Aged 20-30 years 6. Male

Exclusion criteria

Exclusion criteria: 1. Diagnosed as diabetics based on the following criteria: 1.1. Fasting glucose levels equal to or exceeds 126 mg/dL (7.0 mmol/L) 1.2. 2 HOUR glucose equal to or exceeds 200 mg/dL (11.1 mmol/L) 2. Any medical condition which could interfere with the measured variables, including cardiovascular, gastrointestinal, neurological or overt metabolic disorders 3. Currently using medication for acute or chronic illness 4. Competition athletes 5. Overtly sedentary 6. Eating disorders 7. Fear or have adverse reactions to cannulation

Design outcomes

Primary

Measure	Time frame
1. The following haemodynamic parameters will be assessed continuously, starting with a 30 minute baseline and continued after the oral glucose tolerance test (OGTT) for another 120 minutes using a Task Force Monitor: 1.1. Blood pressure (systolic and diastolic) 1.2. Heart rate 1.3. Stroke volume 1.4. Heather index (marker for myocardial contractility) 2. The following blood parameters will be assessed at the end of the 30 minute baseline and after the OGTT every 30 minutes until the end of the OGTT (120 minutes post-drink): 2.1. Plasma glucose, assessed using hexokinase Glucose HK Gen 3 2.2. Plasma insulin, assessed using ELISA	—

Measure

Time frame

1. The following haemodynamic parameters will be assessed continuously, starting with a 30 minute baseline and continued after the oral glucose tolerance test (OGTT) for another 120 minutes using a Task Force Monitor: 1.1. Blood pressure (systolic and diastolic) 1.2. Heart rate 1.3. Stroke volume 1.4. Heather index (marker for myocardial contractility) 2. The following blood parameters will be assessed at the end of the 30 minute baseline and after the OGTT every 30 minutes until the end of the OGTT (120 minutes post-drink): 2.1. Plasma glucose, assessed using hexokinase Glucose HK Gen 3 2.2. Plasma insulin, assessed using ELISA

—

Secondary

Measure	Time frame
1. The following haemodynamic parameters will be assessed continuouslty during the 30 minute baseline and over the 120 minutes following the OGTT: 1.1. Cardiac output, assessed using impedance cardiography 1.2. Total peripheral resistance, assessed by dividing mean blood pressure by cardiac output 1.3. Index of contractility, assessed using impedance cardiography 1.4. Thoracic fluid contact, assessed using impedance cardiography 1.5. Thoracic impedance, assessed using impedance cardiography 1.6. Spectral analysis parameters, assessed using power spectral analysis 1.7. Baroreflex sensitivity, assessed using the sequence technique 2. Central arterial waveform analysis of the following parameters, performed using applanation tonometry prior to each blood sample: 2.1. Central systolic blood pressure 2.2. Central diastolic blood pressure 2.3. Mean blood pressure 2.4. Augmentation index (AIx75) 2.5. Ejection duration index 2.6. Sub-endocardial viability ratio 3. The following anthropometric parameters, assessed using a calibrated scale and a statiometer prior to the OGTT: 3.1. Weight 3.2. Height 3.3. Sitting heigh 3.4. Leg length 3.5. Waist circumference 3.6. Hip circumference 4. The following body composition parameters, assessed using body impedance measurements and the deuterium dilution technique prior to the OGTT: 4.1. Total body fat in kg and % 4.2. Trunk (abdominal) fat in % 4.3. Fat free mass in kg and % 4.4. Skeletal muscle mass in kg and %	—

Measure

Time frame

1. The following haemodynamic parameters will be assessed continuouslty during the 30 minute baseline and over the 120 minutes following the OGTT: 1.1. Cardiac output, assessed using impedance cardiography 1.2. Total peripheral resistance, assessed by dividing mean blood pressure by cardiac output 1.3. Index of contractility, assessed using impedance cardiography 1.4. Thoracic fluid contact, assessed using impedance cardiography 1.5. Thoracic impedance, assessed using impedance cardiography 1.6. Spectral analysis parameters, assessed using power spectral analysis 1.7. Baroreflex sensitivity, assessed using the sequence technique 2. Central arterial waveform analysis of the following parameters, performed using applanation tonometry prior to each blood sample: 2.1. Central systolic blood pressure 2.2. Central diastolic blood pressure 2.3. Mean blood pressure 2.4. Augmentation index (AIx75) 2.5. Ejection duration index 2.6. Sub-endocardial viability ratio 3. The following anthropometric parameters, assessed using a calibrated scale and a statiometer prior to the OGTT: 3.1. Weight 3.2. Height 3.3. Sitting heigh 3.4. Leg length 3.5. Waist circumference 3.6. Hip circumference 4. The following body composition parameters, assessed using body impedance measurements and the deuterium dilution technique prior to the OGTT: 4.1. Total body fat in kg and % 4.2. Trunk (abdominal) fat in % 4.3. Fat free mass in kg and % 4.4. Skeletal muscle mass in kg and %

—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026